PROTECT: Adjuvant Pazopanib After Nephrectomy in Pts With Locally Advanced RCC

Source: 2017 American Society of Clinical Oncology Annual Meeting*
Download Slideset
June 2-6, 2017; Chicago, Illinois
Adjuvant pazopanib at 600 mg after nephrectomy did not prolong DFS compared with placebo in patients with locally advanced RCC.
Format: Microsoft PowerPoint (.ppt)
File Size: 609 KB
Released: June 13, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings